cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.6121748
title: In silico designed mshA-deletion construct-1

description: In silico designed mshA-deletion construct-1
DOI: 10.6084/m9.figshare.6121748.v1
title: In silico designed mshA-deletion construct-1

description: In silico designed mshA-deletion construct-1
DOI: 10.6084/m9.figshare.6121745
title: mshA genomic region in M.tb when replaced with Hyg-2

description: mshA genomic region in M.tb when replaced with Hyg-2
DOI: 10.6084/m9.figshare.6121745.v1
title: mshA genomic region in M.tb when replaced with Hyg-2

description: mshA genomic region in M.tb when replaced with Hyg-2
DOI: 10.6084/m9.figshare.6121742
title: In silico designed mshA-deletion construct-2

description: In silico designed mshA-deletion construct-2
DOI: 10.6084/m9.figshare.6121742.v1
title: In silico designed mshA-deletion construct-2

description: In silico designed mshA-deletion construct-2
DOI: 10.6084/m9.figshare.6121739
title: mshA genomic region in M.tb

description: mshA genomic region in M.tb
DOI: 10.6084/m9.figshare.6121739.v1
title: mshA genomic region in M.tb

description: mshA genomic region in M.tb
DOI: 10.6084/m9.figshare.6121736
title: In silico designed egtE-deletion construct-2

description: In silico designed egtE-deletion construct-2
DOI: 10.6084/m9.figshare.6121733
title: In silico designed egtE-deletion construct-1

description: In silico designed egtE-deletion construct-1
DOI: 10.6084/m9.figshare.6121736.v1
title: In silico designed egtE-deletion construct-2

description: In silico designed egtE-deletion construct-2
DOI: 10.6084/m9.figshare.6121730
title: egtE genomic region.gb

description: egtE genomic region.gb
DOI: 10.6084/m9.figshare.6121733.v1
title: In silico designed egtE-deletion construct-1

description: In silico designed egtE-deletion construct-1
DOI: 10.6084/m9.figshare.6121727
title: In silico designed egtD-deletion construct-1

description: In silico designed egtD-deletion construct-1
DOI: 10.6084/m9.figshare.6121730.v1
title: egtE genomic region.gb

description: egtE genomic region.gb
DOI: 10.6084/m9.figshare.6121727.v1
title: In silico designed egtD-deletion construct-1

description: In silico designed egtD-deletion construct-1
DOI: 10.6084/m9.figshare.6121724
title: In silico designed egtD/native-complementation construct-2

description: In silico designed egtD/native-complementation construct-2
DOI: 10.6084/m9.figshare.6121724.v1
title: In silico designed egtD/native-complementation construct-2

description: In silico designed egtD/native-complementation construct-2
DOI: 10.6084/m9.figshare.6121721
title: egtD genomic region in M.tb

description: egtD genomic region in M.tb
DOI: 10.6084/m9.figshare.6121721.v1
title: egtD genomic region in M.tb

description: egtD genomic region in M.tb
DOI: 10.6084/m9.figshare.6121718
title: In silico designed egtD-deletion construct-2

description: In silico designed egtD-deletion construct-2
DOI: 10.6084/m9.figshare.6121718.v1
title: In silico designed egtD-deletion construct-2

description: In silico designed egtD-deletion construct-2
DOI: 10.6084/m9.figshare.6121715
title: In silico designed egtD/native-complementation construct-1

description: In silico designed egtD/native-complementation construct-1
DOI: 10.6084/m9.figshare.6121715.v1
title: In silico designed egtD/native-complementation construct-1

description: In silico designed egtD/native-complementation construct-1
DOI: 10.6084/m9.figshare.6121709
title: In silico designed egtC-deletion construct-2

description: In silico designed egtC-deletion construct-2
DOI: 10.6084/m9.figshare.6121709.v1
title: In silico designed egtC-deletion construct-2

description: In silico designed egtC-deletion construct-2
DOI: 10.6084/m9.figshare.6121706
title: egtC genomic region in M.tb

description: egtC genomic region in M.tb
DOI: 10.6084/m9.figshare.6121706.v1
title: egtC genomic region in M.tb

description: egtC genomic region in M.tb
DOI: 10.6084/m9.figshare.6121703
title: In silico designed egtC/hsp60-complementation construct

description: In silico designed egtC/hsp60-complementation construct
DOI: 10.6084/m9.figshare.6121703.v1
title: In silico designed egtC/hsp60-complementation construct

description: In silico designed egtC/hsp60-complementation construct
DOI: 10.6084/m9.figshare.6121700
title: In silico designed egtC-deletion construct-1

description: In silico designed egtC-deletion construct-1
DOI: 10.6084/m9.figshare.6121697
title: In silico designed egtB-deletion construct-1

description: In silico designed egtB-deletion construct-1
DOI: 10.6084/m9.figshare.6121700.v1
title: In silico designed egtC-deletion construct-1

description: In silico designed egtC-deletion construct-1
DOI: 10.6084/m9.figshare.6121697.v1
title: In silico designed egtB-deletion construct-1

description: In silico designed egtB-deletion construct-1
DOI: 10.6084/m9.figshare.6121694
title: In silico designed egtB-deletion construct-2

description: In silico designed egtB-deletion construct-2
DOI: 10.6084/m9.figshare.6121694.v1
title: In silico designed egtB-deletion construct-2

description: In silico designed egtB-deletion construct-2
DOI: 10.6084/m9.figshare.6121691
title: In silico designed egtB/hsp60-complementation construct

description: In silico designed egtB/hsp60-complementation construct
DOI: 10.6084/m9.figshare.6121691.v1
title: In silico designed egtB/hsp60-complementation construct

description: In silico designed egtB/hsp60-complementation construct
DOI: 10.6084/m9.figshare.6121688
title: In silico designed egtB/native-complementation construct-2

description: In silico designed egtB/native-complementation construct
DOI: 10.6084/m9.figshare.6121688.v1
title: In silico designed egtB/native-complementation construct-2

description: In silico designed egtB/native-complementation construct
DOI: 10.6084/m9.figshare.6121685
title: egtB genomic region in M.tb

description: egtB genomic region in M.tb
DOI: 10.6084/m9.figshare.6121685.v1
title: egtB genomic region in M.tb

description: egtB genomic region in M.tb
DOI: 10.6084/m9.figshare.6121682
title: In silico designed egtB/native-complementation construct-1

description: In silico designed egtB/native-complementation construct
DOI: 10.6084/m9.figshare.6121682.v1
title: In silico designed egtB/native-complementation construct-1

description: In silico designed egtB/native-complementation construct
DOI: 10.6084/m9.figshare.6121679
title: In silico designed egtA-deletion construct-2

description: In silico designed egtA-deletion construct-2
DOI: 10.6084/m9.figshare.6121679.v1
title: In silico designed egtA-deletion construct-2

description: In silico designed egtA-deletion construct-2
DOI: 10.6084/m9.figshare.6121676
title: In silico designed egtA-deletion construct-1

description: In silico designed egtA-deletion construct-1
DOI: 10.6084/m9.figshare.6121676.v1
title: In silico designed egtA-deletion construct-1

description: In silico designed egtA-deletion construct-1
DOI: 10.6084/m9.figshare.6121673
title: In silico designed egtA/hsp60-complementation construct

description: In silico designed egtA/hsp60-complementation construct
DOI: 10.6084/m9.figshare.6121673.v1
title: In silico designed egtA/hsp60-complementation construct

description: In silico designed egtA/hsp60-complementation construct
DOI: 10.6084/m9.figshare.6121670
title: In silico designed egtA/native-complementation construct-2

description: In silico designed egtA/native-complementation construct-2
DOI: 10.6084/m9.figshare.6121670.v1
title: In silico designed egtA/native-complementation construct-2

description: In silico designed egtA/native-complementation construct-2
DOI: 10.6084/m9.figshare.6121667
title: In silico designed egtA/native-complementation construct-1

description: In silico designed egtA/native-complementation construct
DOI: 10.6084/m9.figshare.6121667.v1
title: In silico designed egtA/native-complementation construct-1

description: In silico designed egtA/native-complementation construct
DOI: 10.6084/m9.figshare.6121664
title: egtA genomic region in M.tb

description: egtA genomic region in M.tb
DOI: 10.6084/m9.figshare.6121664.v1
title: egtA genomic region in M.tb

description: egtA genomic region in M.tb
DOI: 10.6084/m9.figshare.6121658
title: Table 3

description: Multiple linear regression analysis of lumbar spinal stenosis patient data
DOI: 10.6084/m9.figshare.6121658.v4
title: Table 3

description: Multiple linear regression analysis of lumbar spinal stenosis patient data
DOI: 10.6084/m9.figshare.6121655
title: Supplementary Material for: RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain

description: Receptor activator of nuclear factor-κB ligand (RANKL) promotes vascular calcification, while osteoprotegerin (OPG) opposes it by blocking RANKL activity. It remains unclear which vascular cell populations produce and secrete OPG/RANKL. This study characterizes the production of OPG/RANKL from human aortic endothelial and smooth muscle cells (HAECs and HASMCs) under various conditions. HAECs and HASMCs were exposed to inflammatory stimuli (tumor necrosis factor-α or hyperglycemia) or physiological levels of hemodynamic (cyclic) strain. After 72 h, both cells and supernatant media were harvested for assessment of OPG/RANKL production. Based on initial findings, the experiments involving HASMCs were then repeated in the presence of exogenous RANKL. OPG was produced and secreted by HASMCs and (to a considerably lesser degree) HAECs under basal conditions. Inflammatory stimuli upregulated OPG production in both cell populations. Cyclic strain significantly upregulated OPG production in HASMCs. Neither cell population produced RANKL. Exposing HASMCs to exogenous RANKL inhibited basal OPG production and completely abrogated the strain-mediated upregulation of OPG. These data suggest that HASMCs are a significant source of OPG within the vasculature but that RANKL, once present, downregulates this production and appears capable of preventing the “protective” upregulation of OPG seen with HASMCs exposed to physiological levels of cyclic strain.
DOI: 10.6084/m9.figshare.6121655.v1
title: Supplementary Material for: RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain

description: Receptor activator of nuclear factor-κB ligand (RANKL) promotes vascular calcification, while osteoprotegerin (OPG) opposes it by blocking RANKL activity. It remains unclear which vascular cell populations produce and secrete OPG/RANKL. This study characterizes the production of OPG/RANKL from human aortic endothelial and smooth muscle cells (HAECs and HASMCs) under various conditions. HAECs and HASMCs were exposed to inflammatory stimuli (tumor necrosis factor-α or hyperglycemia) or physiological levels of hemodynamic (cyclic) strain. After 72 h, both cells and supernatant media were harvested for assessment of OPG/RANKL production. Based on initial findings, the experiments involving HASMCs were then repeated in the presence of exogenous RANKL. OPG was produced and secreted by HASMCs and (to a considerably lesser degree) HAECs under basal conditions. Inflammatory stimuli upregulated OPG production in both cell populations. Cyclic strain significantly upregulated OPG production in HASMCs. Neither cell population produced RANKL. Exposing HASMCs to exogenous RANKL inhibited basal OPG production and completely abrogated the strain-mediated upregulation of OPG. These data suggest that HASMCs are a significant source of OPG within the vasculature but that RANKL, once present, downregulates this production and appears capable of preventing the “protective” upregulation of OPG seen with HASMCs exposed to physiological levels of cyclic strain.
DOI: 10.6084/m9.figshare.6121640
title: ROS levels under various drugs treament

description: ROS levels under various drugs treament
DOI: 10.6084/m9.figshare.6121637
title: Growth curves under various drugs treatment

description: Growth curves under various drugs treatment
DOI: 10.6084/m9.figshare.6121637.v1
title: Growth curves under various drugs treatment

description: Growth curves under various drugs treatment
DOI: 10.6084/m9.figshare.6121631
title: Calculation of growth inhibitions by drugs

description: Calculation of growth inhibitions by drugs
DOI: 10.6084/m9.figshare.6121631.v1
title: Calculation of growth inhibitions by drugs

description: Calculation of growth inhibitions by drugs
DOI: 10.6084/m9.figshare.6121628
title: M.smegmatis Bacitracin dose response curves

description: M.smegmatis Bacitracin dose response curves
DOI: 10.6084/m9.figshare.6121628.v1
title: M.smegmatis Bacitracin dose response curves

description: M.smegmatis Bacitracin dose response curves
DOI: 10.6084/m9.figshare.6121625
title: M.smegmatis sulfaguanidine dose response curves

description: M.smegmatis sulfaguanidine dose response curves
DOI: 10.6084/m9.figshare.6121625.v1
title: M.smegmatis sulfaguanidine dose response curves

description: M.smegmatis sulfaguanidine dose response curves
DOI: 10.6084/m9.figshare.6121622
title: Raw data of measured metabolic actvities of EgtD and HNMT

description: Raw data of measured metabolic actvities of EgtD and HNMT
DOI: 10.6084/m9.figshare.6121622.v1
title: Raw data of measured metabolic actvities of EgtD and HNMT

description: Raw data of measured metabolic actvities of EgtD and HNMT
DOI: 10.6084/m9.figshare.6121619
title: M.smegmatis azaguanine dose response curves

description: M.smegmatis azaguanine dose response curves
DOI: 10.6084/m9.figshare.6121619.v1
title: M.smegmatis azaguanine dose response curves

description: M.smegmatis azaguanine dose response curves
DOI: 10.6084/m9.figshare.6121616
title: ROS levels in the presence of para-aminobenzoic acid and/or sulfaguanidine

description: ROS levels in the presence of para-aminobenzoic acid and/or sulfaguanidine
DOI: 10.6084/m9.figshare.6121616.v1
title: ROS levels in the presence of para-aminobenzoic acid and/or sulfaguanidine

description: ROS levels in the presence of para-aminobenzoic acid and/or sulfaguanidine
DOI: 10.6084/m9.figshare.6121601
title: Calculated gated population of M.tb mutants flow cytometry

description: Calculated gated population of M.tb mutants flow cytometry
DOI: 10.6084/m9.figshare.6121601.v1
title: Calculated gated population of M.tb mutants flow cytometry

description: Calculated gated population of M.tb mutants flow cytometry
DOI: 10.6084/m9.figshare.6121598
title: Raw and calculated data of bacterial susceptibility to ROS and RNS

description: Raw and calculated data of bacterial susceptibilities to ROS and RNS
DOI: 10.6084/m9.figshare.6121598.v1
title: Raw and calculated data of bacterial susceptibility to ROS and RNS

description: Raw and calculated data of bacterial susceptibilities to ROS and RNS
DOI: 10.6084/m9.figshare.6121595
title: Raw and calculated data of bacterial susceptibilities within THP1 macrophages

description: Raw and calculated data of bacterial susceptibilities within THP1 macrophages
DOI: 10.6084/m9.figshare.6121595.v1
title: Raw and calculated data of bacterial susceptibilities within THP1 macrophages

description: Raw and calculated data of bacterial susceptibilities within THP1 macrophages
DOI: 10.6084/m9.figshare.6121586
title: egtE mutant aggregation-3

description: egtE mutant aggregation-3
DOI: 10.6084/m9.figshare.6121586.v1
title: egtE mutant aggregation-3

description: egtE mutant aggregation-3
DOI: 10.6084/m9.figshare.6121583
title: egtE mutant aggregation-1

description: egtE mutant aggregation-1
DOI: 10.6084/m9.figshare.6121583.v1
title: egtE mutant aggregation-1

description: egtE mutant aggregation-1
DOI: 10.6084/m9.figshare.6121580
title: egtE mutant inability to form biofilm-1

description: egtE mutant inability to form biofilm-1
DOI: 10.6084/m9.figshare.6121580.v1
title: egtE mutant inability to form biofilm-1

description: egtE mutant inability to form biofilm-1
DOI: 10.6084/m9.figshare.6121577
title: egtE mutant inability to form biofilm-2

description: egtE mutant inability to form biofilm-2
DOI: 10.6084/m9.figshare.6121577.v1
title: egtE mutant inability to form biofilm-2

description: egtE mutant inability to form biofilm-2
DOI: 10.6084/m9.figshare.6121574
title: egtE mutant aggregation-2

description: egtE mutant aggregation-2
DOI: 10.6084/m9.figshare.6121574.v1
title: egtE mutant aggregation-2

description: egtE mutant aggregation-2
DOI: 10.6084/m9.figshare.6121505
title: Supplementary Material for: Study of the Association of <b><i>PEAR1</i></b>,<b><i> P2Y12</i></b>, and <b><i>UGT2A1</i></b> Polymorphisms with Platelet Reactivity in Response to Dual Antiplatelet Therapy in Chinese Patients

description: <b><i>Objectives:</i></b> Genetic variation is thought to contribute to considerable interindividual variability in platelet function, and there is a pressing need to identify genetic markers that can be used to predict the response to treatment. Our study investigated whether <i>PEAR1</i>,<i> P2Y12</i>, and <i>UGT2A1</i> polymorphisms were associated with platelet reactivity in response to dual antiplatelet therapy in Chinese patients with acute coronary syndrome. <b><i>Methods:</i></b> Patients with inhibition of platelet aggregation (IPA) &lt; 30% after treatment were classified as the high platelet reactivity (HPR) group. Patients with IPA &gt; 30% were classified as the normal platelet reactivity (NPR) group. ADP-induced platelet aggregation was measured by thromboelastography (TEG) platelet-mapping assay. Thirteen single nucleotide polymorphisms (SNPs) of <i>PEAR1</i>, <i>P2Y12</i> and <i>UGT2A1</i> were genotyped using the Mass­ARRAY platform. <b><i>Results:</i></b> Seven SNPs were significantly associated with ADP-induced platelet aggregation by univariate analysis. Major allele G at rs12041331, minor allele G at rs2644592, minor allele C at rs11264580, and minor allele C at rs11249454 were significantly associated with HPR, whereas minor allele T at rs57731889, minor allele A at rs16863356, and minor allele T at rs7634096 were significantly associated with NPR. The mean IPA was significantly lower in patients suffering recurrent ischemic events than in patients without recurrent events in our study (<i>p =</i> 0.048). <b><i>Conclusions:</i></b> Our findings suggest that <i>PEAR1</i>,<i> P2Y12</i>, and<i> UGT2A1</i> genetic variants may be potential biomarkers that can be used to guide clinical applications of clopidogrel and aspirin in Chinese patients.
DOI: 10.6084/m9.figshare.6121499
title: Table 2

description: Correlation analysis to identify variables possibly associated with maximum trunk flexion angle in lumbar spinal stenosis patients
DOI: 10.6084/m9.figshare.6121499.v1
title: table 2.xlsx

description: Correlation analysis to identify variables possibly associated with maximum trunk flexion angle in lumbar spinal stenosis patients
DOI: 10.6084/m9.figshare.6121499.v2
title: Table 2

description: Correlation analysis to identify variables possibly associated with maximum trunk flexion angle in lumbar spinal stenosis patients
DOI: 10.6084/m9.figshare.6121499.v3
title: Table 2

description: Correlation analysis to identify variables possibly associated with maximum trunk flexion angle in lumbar spinal stenosis patients
DOI: 10.6084/m9.figshare.6121499.v5
title: Table 2

description: Correlation analysis to identify variables possibly associated with maximum trunk flexion angle in lumbar spinal stenosis patients
DOI: 10.6084/m9.figshare.6121499.v4
title: Table 2

description: Correlation analysis to identify variables possibly associated with maximum trunk flexion angle in lumbar spinal stenosis patients
DOI: 10.6084/m9.figshare.6121496
title: Supplementary Material for: A Novel <b><i>SCN5A</i></b> Variant Associated with Abnormal Repolarization, Atrial Fibrillation, and Reversible Cardiomyopathy

description: A variety of life-threating arrhythmias are caused by mutations in the cardiac voltage-gated sodium channel encoded by the<i> SCN5A</i> gene. In this study, we report a novel loss-of-function <i>SCN5A</i> variant, p.Ile1343Val (c.4027A&gt;G), identified in a 42-year-old proband who presented with an unusual ECG with abnormal repolarization with biphasic T-waves in anteroseptal leads, persistent atrial fibrillation (AF), intermittent left bundle branch block (LBBB), and reversible cardiomyopathy. The patient did not meet the diagnostic criteria for Brugada syndrome, long QT syndrome, or any other known <i>SCN5A</i>-associated phenotype. Characterization of the biophysical properties of the variant by in vitro<i></i> patch clamp experiments revealed a reduced Na<sup>+</sup> current with no effect on the inactivation kinetics of the channel. This loss-of-function of Na<sup>+</sup> current could explain the intermittent LBBB as well as the AF. In conclusion, we describe a unique combination of electrical and structural abnormalities associated with a novel <i>SCN5A</i> variant. Our findings broaden the spectrum of cardiac phenotypes associated with <i>SCN5A</i> channelopathy, underlining the complex clinical manifestations of genetic variations within this gene.
DOI: 10.6084/m9.figshare.6121457
title: Table 1

description: Clinical characteristics on the sample population
DOI: 10.6084/m9.figshare.6121457.v1
title: table 1.xlsx

description: Clinical characteristics on the sample population
DOI: 10.6084/m9.figshare.6121457.v2
title: Table 1

description: Clinical characteristics on the sample population
DOI: 10.6084/m9.figshare.6121457.v3
title: Table 1

description: Clinical characteristics on the sample population
DOI: 10.6084/m9.figshare.6121457.v4
title: Table 1

description: Clinical characteristics on the sample population
DOI: 10.6084/m9.figshare.6121436
title: Network Visualization Map Data

description: Data used to generate co-occurrence network map of publication data keywords using the VOSviewer server (Version 1.6.5). Approximately 227,000 keywords were extracted from citation titles and abstracts from the Web of Science. A network was computed for a total of 2,460 terms selected by the full-counting method and relevance scoring as implemented within VOSviewer. For analysis, we reviewed co-occurrence network maps for thresholds between 5 and 40. The default cutoff of 30 as the number of term co-occurrence is shown.
DOI: 10.6084/m9.figshare.6121436.v1
title: Network Visualization Map Data

description: Data used to generate co-occurrence network map of publication data keywords using the VOSviewer server (Version 1.6.5). Approximately 227,000 keywords were extracted from citation titles and abstracts from the Web of Science. A network was computed for a total of 2,460 terms selected by the full-counting method and relevance scoring as implemented within VOSviewer. For analysis, we reviewed co-occurrence network maps for thresholds between 5 and 40. The default cutoff of 30 as the number of term co-occurrence is shown.
DOI: 10.6084/m9.figshare.6121412
title: Xenacoelomorph neuropeptide precursors

description: Amino acid sequences of xenacoelomorph neuropeptide precursors.
DOI: 10.6084/m9.figshare.6121412.v1
title: Xenacoelomorph neuropeptide precursors

description: Amino acid sequences of xenacoelomorph neuropeptide precursors.
DOI: 10.6084/m9.figshare.6121397
title: Xenacoelomorph neuropeptide GPCRs

description: Amino acid sequences of xenacoelomorph neuropeptide GPCRs
DOI: 10.6084/m9.figshare.6121394
title: 2017 RCSB.org Survey Data

description: User Survey hosted at SurveyMonkey during the month of October 2017, and promoted on RCSB.org, PDB101.rcsb.org, message boards, and social media.
DOI: 10.6084/m9.figshare.6121394.v1
title: 2017 RCSB.org Survey Data

description: User Survey hosted at SurveyMonkey during the month of October 2017, and promoted on RCSB.org, PDB101.rcsb.org, message boards, and social media.
DOI: 10.6084/m9.figshare.6121382
title: Mass spectrometry data of Xenacoelomorph neuropeptides

description: Mass spectrometric data of peptide extracts from three Xenacoelomorpha species Convolutriloba macropyga (Cmac R1), Hofstenia miamia (Hmia R2), Isodiametra pulchra (Ipul R3). Data includes scores and spectra of identified peptides.